Skip to main content

Table 1 Percentage of cytotoxicity found in each group and positive (CTR +) and negative (CTR−) controls as determined by quantification of DNA released to the culture medium (DNA) and WST1 metabolic function after 24 h and 48 h of ex vivo follow-up

From: Generation of a novel human dermal substitute functionalized with antibiotic-loaded nanostructured lipid carriers (NLCs) with antimicrobial properties for tissue engineering

  FSS-AMK 10 FSS-AMK 100 FSS-AMK300 FSS-AMK 1000 FSS-SCM 10 FSS-SCM 100 FSS-SCM300 FSS-SCM 1000 FSS-CTR 10 FSS-CTR 100 FSS-CTR300 FSS-CTR 1000 CTR +  CTR-
DNA
 24 h 0 ± 0a 0 ± 0a 0 ± 0a 3.7 ± 0.3a,b 0 ± 0a 0 ± 0a 1.1 ± 0.1a,b 0.7 ± 0.2a,b 0 ± 0a 0 ± 0a 0 ± 0a 0 ± 0a 0 ± 0.2a 100 ± 0.5b
 48 h 0 ± 0a 0 ± 0a 0 ± 0a 4.7 ± 1a,b 8.7 ± 1.1a,b 0 ± 0a 0 ± 0a 6 ± 0.8a,b 0 ± 0.1a 0 ± 0a 0 ± 0a 1 ± 2.3a,b 0 ± 0.1a 100 ± 9.2b
WST1
 24 h 14.6 ± 7.1a,b 8.4 ± 3.7a,b 3.7 ± 5.5a,b 0 ± 0a 8.7 ± 8.2a,b 5.8 ± 5.3a,b 0 ± 0a 0 ± 0a 4.6 ± 3.8a,b 10.4 ± 9.2a,b 6.1 ± 3a,b 3.6 ± 3.9a,b 0 ± 5.6a 100 ± 0.1b
 48 h 11.1 ± 10.7a 0.2 ± 0.6a 9.2 ± 3.6a 3 ± 3.7a 5.9 ± 5.7a 2.5 ± 2.6a 0 ± 0a 0 ± 0a 3.4 ± 4.4a 7.7 ± 7.3a 1.4 ± 2.7a 0 ± 0a 0 ± 19.1a 100 ± 0.1b
  1. aDifferences with negative controls are statistically significant
  2. bDifferences with positive controls are statistically significant. FSS: functionalized human dermal skin substitutes containing different types of NLCs (AMK, SCM or CTR) at different concentrations (10, 100, 300 or 1000 µg/ml)